Bhagiradha Chemicals & Industries Ltd. (BHAGCHEM) AI Stock Analysis

• Market Cap: ₹23.36B
• Dividend Yield: 0.06%
• Average Volume (3M): 34.10K
• Price to Earnings (P/E): 152.6
• Beta (1Y): 0.90
• Revenue Growth: 22.08%
• EPS Growth: -50.11%
• Country: IN
• Employees: 530
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): 0.36
• Shares Outstanding: 129,669,080
• 10 Day Avg. Volume: 94,811
• 30 Day Avg. Volume: 34,100
• PEG Ratio: -7.15
• Price to Book (P/B): 5.06
• Price to Sales (P/S): 7.84
• P/FCF Ratio: -11.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: ₹189.00 ▼(-22.49% Downside)
• Action: Reiterated Date: 01/06/26
• Date: Action: Reiterated 01/06/26

Overall score reflects solid financial performance driven by strong revenue growth and stable operating margins, partially offset by weak cash-flow conversion and increased leverage. Technicals are notably weak with price below all key moving averages and negative MACD, and valuation is strained due to an extremely high P/E despite a strong dividend yield.

Positive Factors

Consistent Revenue Growth

Sustained top-line expansion indicates durable demand for the company’s products in the agricultural inputs market. Consistent revenue growth supports scale advantages, long-term contract leverage and reinvestment capacity, strengthening the firm's ability to fund R&D, capex or dividends over multiple years.

Stable Operating Margins

Stable EBIT/EBITDA margins point to operational efficiency and pricing power in the company’s core processes. Persistent margin stability helps protect profitability through input cost cycles, supports free cash generation potential over time, and indicates management controls on operating leverage.

Healthy Equity Base

A robust equity ratio provides a financial cushion to absorb shocks and fund strategic investments without immediate refinancing. This structural strength enhances creditworthiness, preserves borrowing capacity for capex or working capital, and supports long-term resilience in cyclical agricultural markets.

Negative Factors

Weak Cash-Flow Conversion

Volatile operating cash flow and a sharply negative free cash flow year reduce internal funding for growth and dividends, forcing reliance on external financing. Over a multi-quarter horizon this can constrain strategic investments, raise financing costs, and magnify risks if capex or working capital remain elevated.

Rising Leverage

An uptick in leverage reduces financial flexibility and increases interest burden risk if earnings weaken. Persistently higher debt levels can curtail ability to fund opportunistic investments, raise refinancing exposure in downturns, and compress margins if interest costs rise or cash flows remain uneven.

Earnings Volatility / EPS Decline

A large decline in EPS signals volatile profitability and weaker earnings quality, which can undermine reinvestment capacity and dividend sustainability. If earnings remain inconsistent, the company may face difficulty building retained earnings and maintaining strategic flexibility over the coming quarters.

Bhagiradha Chemicals & Industries Ltd. Business Overview & Revenue Model

Company Description

Bhagiradha Chemicals & Industries Limited manufactures and sells agrochemicals in India. The company offers insecticides, such as chlorpyrifos, chlorpyrifos-methyl, diafenthiuron, fipronil, dinotefuran, thiamethoxam, pymetrozine, and imidacloprid; fungicides that include azoxystrobin; herbicides comprising triclopyr, cloquintocet-mexyl, and clodinafop-propargyl; and specialty intermediates, such as 2,6-dichloroaniline. It also provides contract manufacturing services. In addition, it exports its products to the United States, Brazil, Columbia, Argentina, Mexico, Costa Rica, Germany, the United Kingdom, France, Portugal, Chile, Italy, Belgium, Israel, Turkey, Iran, Indonesia, Taiwan, Malaysia, New Zealand, the United Arab Emirates, Korea, and Australia. The company was incorporated in 1993 and is headquartered in Hyderabad, India.

How the Company Makes Money

null

Bhagiradha Chemicals & Industries Ltd. Financial Statement Overview

Summary

Solid income statement trends with consistent revenue growth and stable EBIT/EBITDA margins, supported by a healthy equity base. Score is tempered by cash-flow weakness (volatile operating cash flow and sharply negative free cash flow in 2025) and a modest rise in leverage.

Income Statement

The company has shown consistent revenue growth over the years, with a notable increase in total revenue from 2021 to 2025. Gross profit margins have been relatively strong, although there was a decrease in net profit margin in 2025 due to reduced net income. EBIT and EBITDA margins are stable, indicating efficient operations, though slightly impacted by the decrease in EBIT in 2025.

Balance Sheet

The balance sheet reflects a strong equity base with a healthy equity ratio, indicating financial stability. However, the debt-to-equity ratio has increased slightly over the years, suggesting a moderate leverage risk. ROE has been fluctuating due to varying net income levels, requiring attention for consistent profitability.

Cash Flow

The cash flow statement shows volatility, with significant negative free cash flow in 2025 due to high capital expenditures. The operating cash flow to net income ratio indicates operational challenges in converting income to cash, necessitating improved cash management strategies.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	4.89B	4.40B	4.07B	5.02B	4.35B	3.18B
Gross Profit	1.70B	1.62B	915.80M	1.21B	1.03B	743.82M
EBITDA	441.53M	462.27M	431.76M	760.20M	652.34M	451.55M
Net Income	121.93M	138.57M	182.21M	451.52M	357.48M	233.19M
Balance Sheet
Total Assets	10.39B	9.33B	5.76B	4.47B	3.42B	2.73B
Cash, Cash Equivalents and Short-Term Investments	143.57M	301.28M	484.22M	29.41M	22.03M	5.88M
Total Debt	1.89B	889.14M	616.39M	501.97M	807.70M	624.13M
Total Liabilities	3.50B	2.51B	1.62B	1.34B	1.52B	1.18B
Stockholders Equity	6.90B	6.82B	4.14B	3.13B	1.90B	1.56B
Cash Flow
Free Cash Flow	-1.10B	-3.05B	-447.67M	-459.32M	-106.45M	-178.37M
Operating Cash Flow	-58.47M	-527.99M	342.88M	138.94M	66.06M	35.59M
Investing Cash Flow	-1.03B	-2.00B	-1.21B	-596.13M	-171.17M	-207.60M
Financing Cash Flow	933.60M	2.72B	883.15M	464.65M	124.17M	148.03M

Bhagiradha Chemicals & Industries Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 243.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BHAGCHEM, the sentiment is Negative. The current price of 243.85 is above the 20-day moving average (MA) of 196.91, above the 50-day MA of 207.89, and below the 200-day MA of 252.17, indicating a bearish trend. The MACD of -7.05 indicates Positive momentum. The RSI at 30.71 is Neutral, neither overbought nor oversold. The STOCH value of 9.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BHAGCHEM.

Bhagiradha Chemicals & Industries Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSECTICID	68 Neutral	₹16.73B	49.77	―	0.71%	6.86%	15.64%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
BHAGCHEM	60 Neutral	₹23.36B	152.58	―	0.06%	22.08%	-50.11%
MBAPL	58 Neutral	₹39.70B	29.10	―	0.12%	65.92%	224.35%
MOL	46 Neutral	₹10.82B	-115.81	―	―	―	―
NFL	45 Neutral	₹33.99B	8.30	―	1.77%	-7.78%	-70.89%

Bhagiradha Chemicals & Industries Ltd. Corporate Events

Bhagiradha Chemicals Plans Non-Deal Roadshow Meetings in Mumbai

Bhagiradha Chemicals & Industries Ltd. has scheduled a non-deal roadshow in Mumbai on 11 March 2026, organized by Equirus Securities, where company officials will hold one-on-one meetings with analysts and institutional investors. The interactions will be restricted to publicly available information with no unpublished price-sensitive data shared, and the company notes that the schedule may change due to exigencies while fulfilling its disclosure obligations under SEBI’s listing regulations.